Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth - GBI Research Reports

Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth

Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth - GBI Research Reports
Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth
Published Jun 25, 2011
118 pages — Published Jun 25, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Researchs report, Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth, provides in-depth analysis of unmet needs, drivers and barriers that impact the global kidney and renal diseases therapeutics market. The report analyzes the markets for kidney and renal diseases therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Scope

The scope of this report includes -
- Annualized market data for the kidney and renal diseases therapeutics market from 2001 to 2010, forecast forward to 2017
- Analysis of the leading therapeutic segments.
- Analysis of the kidney and renal diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the kidney and renal diseases therapeutics market including market size, annual cost of therapy, and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2010 in the global kidney and renal diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

  
Source:
Document ID
GBIHC097MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents38
  List of Tables62
  List of Figures83
Kidney and Renal Diseases Therapeutics Market to 2017 - Introduction112
  GBI Research Report Guidance121
Kidney and Renal Diseases Therapeutics Market to 2017 - Market Overview137
  Introduction131
  Revenue Forecasts for the Global Kidney and Renal Disease Market131
    Revenue131
    Annual Cost of Treatment (ACT)141
  Treatment Usage Patterns151
    Diseased Population161
    Treatment Seeking Population171
    Diagnosis Population181
    Prescription Population191
Kidney and Renal Diseases Therapeutics Market to 2017 - Geographical Landscape207
  Revenue Analysis by Geography201
  The US211
    Revenue211
    Annual Cost of Treatment221
  Top Five Countries of Europe231
    Revenue231
    Annual Cost of Treatment241
  Japan251
    Revenue251
    Annual Cost of Treatment261
Kidney and Renal Diseases Therapeutics Market to 2017 - Therapeutic Landscape2740
  Chronic Kidney Diseases Market271
    Introduction271
    Revenue273
    Annual Cost of Treatment301
    Treatment Usage Patterns311
      Diseased Population321
      Treatment Seeking Population331
      Diagnosed Population341
      Prescription Population351
    Drivers and Barriers for the Chronic Kidney Diseases Market361
    Drivers for the Chronic Kidney Disease Market361
      Increasing Prevalence of Chronic Kidney Disease361
      Increasing Treatment Options361
    Barriers for the Chronic Kidney Disease Market361
      Low Awareness and Poor Treatment Seeking Behavior361
  Renal Anemia Market371
    Introduction371
    Revenue373
    Annual Cost of Treatment401
    Treatment Usage Patterns411
      Diseased Population421
      Treatment Seeking Population431
      Diagnosed Population441
      Prescription Population451
    Drivers and Barriers for the Renal Anemia Market461
    Drivers for the Renal Anemia Market461
      Increasing Prevalence of Renal Anemia461
      Increasing Treatment Options461
    Barriers for the Renal Anemia Market461
      Low Awareness and Poor Treatment Seeking Behavior461
  Diabetic Nephropathy Market471
    Introduction471
    Revenue473
    Annual Cost of Treatment501
    Treatment Usage Patterns511
      Diseased Population521
      Treatment Seeking Population531
      Diagnosed Population541
      Prescription Population551
    Drivers and Barriers for the Diabetic Nephropathy Market561
    Drivers for the Diabetic Nephropathy Market561
      Increasing Prevalence of Diabetic Nephropathy561
    Barriers for the Diabetic Nephropathy Market561
      Low Awareness and Poor Treatment Seeking Behavior561
  Acute Kidney Injury Market571
    Introduction571
    Revenue582
    Annual Cost of Treatment601
    Treatment Usage Patterns611
      Diseased Population621
      Treatment Seeking Population631
      Diagnosed Population641
      Prescription Population651
    Drivers and Barriers for the Acute Kidney Injury Market661
    Drivers for the Acute Kidney Injury Market661
      Increasing Prevalence of Acute Kidney Injury (AKI)661
      Increasing Diagnostic Options Biomakers: Proteomic Analysis661
    Barriers for the Acute Kidney Injury Nephropathy Market661
      Low Awareness and Poor Treatment Seeking Behavior661
Kidney and Renal Diseases Therapeutics Market to 2017 - Product Pipeline Analysis6726
  Introduction671
    Research and Development Pipeline Chronic Kidney Disease (CKD)686
    Research and Development Pipeline Renal Anemia (RA)742
    Research and Development Pipeline Diabetic Nephropathy (DN)763
    Research and Development Pipeline Acute Kidney Injury (AKI)793
  Profiles of Promising Drugs in the Kidney and Renal Disease Market821
    AMG 223821
      Overview821
      Mechanism of Action821
      Clinical Study Details821
    AST-120831
      Overview831
      Mechanism of Action831
      Clinical Study Details831
    CellCept841
      Overview841
      Mechanism of Action841
      Clinical Study Details841
    Ferinject851
      Overview851
      Mechanism of Action851
      Clinical Study Details851
    Genz-644470861
      Overview861
      Mechanism of Action861
      Clinical Study Details861
    Hematide871
      Overview871
      Mechanism of Action871
      Clinical Study Details871
    HEPLISAV871
      Overview871
      Mechanism of Action871
      Clinical Study Details871
    Heptar881
      Overview881
      Mechanism of Action881
      Clinical Study Details881
    SBR759891
      Overview891
      Mechanism of Action891
      Clinical Study Details891
    Sulodexide901
      Overview901
      Mechanism of Action901
      Clinical Study Details901
    YM533901
      Overview901
      Mechanism of Action901
      Clinical Study Details901
    Zuragen911
      Overview911
      Mechanism of Action911
      Clinical Study Details911
    Olmetec911
      Overview911
      Mechanism of Action911
      Clinical Study Details921
Kidney and Renal Diseases Therapeutics Market to 2017 - Competitive Landscape9311
  Market Share Analysis931
  Amgen Inc.941
    Company Overview941
    Business Overview941
    SWOT Analysis951
  Merck &Co., Inc.961
    Company Overview961
    Business Overview961
    SWOT Analysis971
  Bristol-Myers Squibb Company981
    Company Overview981
    Business Overview981
    SWOT Analysis991
  Hoffmann-La Roche Inc.1001
    Company Overview1001
    Business Overview1001
    SWOT Analysis1011
  Shire Inc.1021
    Company Overview1021
    Business Overview1021
    SWOT Analysis1031
Kidney and Renal Diseases Therapeutics Market to 2017 - M&A Landscape10410
  M&A Deals1041
    Deal Summary1051
      SICOR Pharmaceuticals reacquired the US Rights of Calcitriol from AAIPharma in 20041051
      Amgen Acquired Ilypsa for $420m in 20071051
      Takeda Pharmaceuticals acquired TAP Pharmaceutical from Abbott Laboratories in 20081051
      Akela Pharma merged with Nventa Biopharmaceuticals in 20091051
      Astellas Pharma acquired assets and rights of Diannexin from Pharmaceutical Product in 20101051
      GlaxoSmithKline acquired additional 8.3% Stake in JCR Pharmaceuticals in 20101061
      North Country Health Services merged with Sanford Health in 20101061
      SolAmor Hospice acquired Countryside Hospice from High Street Capital in 20101061
    Deals by Geography1071
  Licensing Deals1081
    Summary of Licensing Deals (2009-2010)1091
      Kureha entered into licensing agreement with Mitsubishi Tanabe in 20091091
      Reata Pharmaceuticals entered into licensing agreement with Kyowa Hakko Kirin in 20101091
      Quark Pharmaceuticals entered into option licensing agreement with Novartis Pharmaceuticals for QPI-1002 in 20101101
  Co-development Deals1111
    Summary of Co-development Deals (2009-2010)1121
      GlaxoSmithKline entered into an agreement with Concert Pharmaceuticals in 20091121
      Nanomi entered into co-development agreement with Consortium in 20091121
      Abbott entered into an agreement with Reata Pharmaceuticals in 20101121
      Eli Lilly entered into co-development agreement with Boehringer Ingelheim in 20111131
Kidney and Renal Diseases Therapeutics Market to 2017 - Appendix1145
  Market Definitions1141
  Abbreviations1141
  Research Methodology1153
    Coverage1151
    Secondary Research1161
    Primary Research1161
    Expert Panel Validation1171
  Contact Us1181
  Disclaimer1181
  Sources1181

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth" Jun 25, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Kidney-and-Renal-Diseases-Therapeutics-Market-to-2017-Strong-Pipeline-and-Unmet-Need-Due-to-Poor-Safety-Profiles-to-Create-Opportunities-for-Growth-2115-267>
  
APA:
GBI Research Reports. (2011). Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth Jun 25, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Kidney-and-Renal-Diseases-Therapeutics-Market-to-2017-Strong-Pipeline-and-Unmet-Need-Due-to-Poor-Safety-Profiles-to-Create-Opportunities-for-Growth-2115-267>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.